Patents by Inventor Scott McComb

Scott McComb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250051443
    Abstract: Here is disclosed isolated or purified monoclonal antibodies, or an antigen-binding fragments thereof, which binds to human CD3, and which comprises: a CDRH1 amino acid sequence of SEQ ID NO: 150, a CDRH2 amino acid sequence of SEQ ID NO: 151, a CDRH3 amino acid sequence of SEQ ID NO: 152, a CDRL1 amino acid sequence of SEQ ID NO: 153, a CDRL2 amino acid sequence of SEQ ID NO: 154, and a CDRL3 amino acid sequence of SEQ ID NO: 155. Also provided are recombinant polypeptides comprising said monoclonal antibody, or an antigen-binding fragment thereof, such as multivalent antibodies, including bispecific T-cell engagers. Also described are chimeric antigen receptors (CARs) for CAR-T therapy comprising any one of the monoclonal antibodies, or antigen-binding fragments thereof. Nucleic acids encoding the aforementioned antibodies, fragments, and polypeptides are also disclosed, along with therapeutic applications in the treatment of and autoinflammatory disease or cancer.
    Type: Application
    Filed: October 5, 2022
    Publication date: February 13, 2025
    Inventors: Anne MARCIL, Robert PON, Scott MCCOMB, Umar IQBAL
  • Publication number: 20250000976
    Abstract: Herein are provided anti-BCMA single domain antibodies (sdAb) prepared byte immunizing a llama with the ecto-domain of human B-cell maturation antigen (BCMA) that is preferentially expressed by mature B lymphocytes. By constructing a library of the heavy chain repertoire generated, VHH antibodies specific to the immunogen were isolated. The 13 unique example antibodies initially produced comprise CDR1, CDR2, and CDR3 sequences corresponding, respectively to SEQ NOs: 1-3, 4-6, 7-9, 10-12, 13-15, 16-18, 19-21, 22-24, 25-27, 28-30, 31-33, 34-36, 37-39; and related sequences. Also provided are multivalent antibodies comprising any one of the sdAbs, including bispecific T-cell engagers, bispecific killer cell engagers (BiKEs), and trispecific killer cell engagers (TriKEs). Also described are chimeric antigen receptors (CARs) for CAR-T therapy comprising any one of the aforementioned sdAbs.
    Type: Application
    Filed: October 5, 2022
    Publication date: January 2, 2025
    Inventors: Mehdi ARBABI-GHAHROUDI, Risini WEERATNA, Scott MCCOMB, Cunle WU
  • Publication number: 20240156870
    Abstract: Herein are provided anti-EGFR single domain antibodies (sdAb) prepared by immunizing a llama with recombinant human EGFRvIII. VHH antibodies specific to EGFR were isolated. The example antibodies initially produced comprise CDR1, CDR2, and CDR3 sequences corresponding, respectively to SEQ NOs: 1-3, 4-6, 7-9, 10-12, 13-15, 16-18, 19-21, 22-24, 25-27, 28-30, 31-33, 34-36, 37-39, 40-42, 43-45, and 46-48; and related sequences, including humanized variants. Also provided are multivalent antibodies comprising any one of the sdAbs, including bispecific T-cell engagers, bispecific killer cell engagers (BiKEs), and trispecific killer cell engagers (TriKEs). Also described are chimeric antigen receptors (CARs) for CAR-T therapy comprising any one of the aforementioned sdAbs. Uses of these molecules in the treatment of cancer are also described, in particularly EGFR-high cancers. Hinge lengths may be selected to achieve desired activities, such as high activity or high selectivity for target vs. non-target cells.
    Type: Application
    Filed: October 28, 2021
    Publication date: May 16, 2024
    Inventors: Kevin HENRY, Martin ROSSOTTI, Mehdi ARBABI-GHAHROUDI, Scott MCCOMB, Risini WEERATNA, Jamshid TANHA
  • Publication number: 20240076406
    Abstract: The present disclosure relates to a single domain antibody that specifically binds to the epitope in the catalytic domain of carbonic anhydrase IX (CA-IX). The single domain antibody has a dissociation constant (KD) of 1×10?7 or lower for a monomeric form of human CA-IX and/or a dimeric form of human CA-IX.
    Type: Application
    Filed: January 21, 2022
    Publication date: March 7, 2024
    Applicant: National Research Council of Canada
    Inventors: Anne EG LENFERINK, Mehdi ARBABI GHAHROUDI, Nazanin ROHANI LARIJANI, Scott MCCOMB
  • Publication number: 20230265185
    Abstract: Herein are provided anti-CD22 single domain antibodies (sdAb) prepared by immunizing a llama with the extracellular domain of the predominant human CD22 isoform. By constructing a library of the heavy chain repertoire generated, VHH antibodies specific to the immunogen were isolated. The 27 example antibodies initially produced comprise CDR1, CDR2, and CDR3 sequences corresponding, respectively to SEQNOs: 1-3, 4-6, 7-9, 10-12, 13-15, 16- 18, 19-21, 22-24, 25-27, 28-30, 31-33, 34-36, 37-39, 40-42, 43-45, 46-48, 49-51, 52-54, 55- 57, 58-60, 61-63, 64-66, 67-69, 70-72, 73-75, 75-78, and 79-81; and related sequences. Also provided are multivalent antibodies comprising any one of the sdAbs, including bispecific T-cell engagers, bispecific killer cell engagers (BiKEs), and trispecific killer cell engagers (TriKEs). Also described are chimeric antigen receptors (CARs) for CAR-T therapy comprising any one of the aforementioned sdAbs. Uses of these molecules in the treatment of cancer are also described.
    Type: Application
    Filed: July 27, 2021
    Publication date: August 24, 2023
    Inventors: Scott MCCOMB, Risini WEERATNA, Mehdi ARBABI-GHAHROUDI, Tina NGUYEN, Cunle WU
  • Publication number: 20220323495
    Abstract: The present disclosure relates to antigen-binding agents that specifically bind to epidermal growth factor receptor variant III (EGFRvIII). Antigen-binding agents of the present disclosure include antibodies and antigen-binding fragments thereof, chimeric antigen receptors (CARs) and bi-specific T-cell engagers (BITE!), bispecific killer cell engagers (BiKEs) and bispecific killer cell engagers (TriKEs). Nucleic acid molecules and vectors expressing antibodies, antigen-binding fragments, CARs, BiTEs, BiKEs or TriKEs are also encompassed by the present disclosure. Immune cells engineered to express CARs, BiTEs, BiKEs or TriKEs may be used to specifically recognize and kill cells expressing EGFRvIII.
    Type: Application
    Filed: March 23, 2020
    Publication date: October 13, 2022
    Inventors: Scott McComb, Risini Dhammika WEERATNA, Maria JARAMILLO, Anne MARCIL, Traian SULEA, Cunle WU, Darin BLOEMBERG
  • Publication number: 20140048154
    Abstract: A water device comprising at least a water-carrying vessel and head, and a structure configured to blend in with a landscape environment wherein the structure conceals at least a portion of the water-carrying vessel while leaving the head exposed. Depending on the configuration, the structure may resemble a rock, bark, plant trunk, stone, bedding material, pavers, edge brick and similar decorative landscaping items and may be fabricated of resins, cements, epoxies, fillers, polymers, metals, recycled materials. Natural articles like stone and bark may also be used. Illumination systems, speakers and self-contained music systems may be included as well. Power may be provided by batteries, electricity or solar panels.
    Type: Application
    Filed: August 23, 2012
    Publication date: February 20, 2014
    Inventor: Melvin Scott McCombs
  • Publication number: 20140048621
    Abstract: A water device comprising at least a water-carrying vessel and head, and a structure configured to blend in with a landscape environment wherein the structure conceals at least a portion of the water-carrying vessel while leaving the head exposed. Depending on the configuration, the structure may resemble a rock, bark, plant trunk, stone, bedding material, pavers, edge brick and similar decorative landscaping items and may be fabricated of resins, cements, epoxies, fillers, polymers, metals, recycled materials. Natural articles like stone and bark may also be used.
    Type: Application
    Filed: August 17, 2012
    Publication date: February 20, 2014
    Inventors: William H. Burke, Melvin Scott McCombs, Rob Guy
  • Patent number: 8092593
    Abstract: Compositions for fabricating architectural works wherein the compositions utilize one or more cement materials, additives, fibers and recycled glass. Exemplary cement materials include Portland cement, calcium aluminate, fly ash and/or E glass. Exemplary additives include boric acid, citric acid, lithium, plasticizer and/or methylcellulose ethers. Exemplary fibers include polyvinyl alcohol (PVA) and/or micro-fibers. Crushed recycled glass is used as an aggregate or non-reactive material. Other ingredients may be used including: sodium hydroxide, potassium hydroxide and hydrated lime to alter the PH; ferrous sulfate, mono-potassium phosphate, or manganese carbonate and magnesium sulfate as color enhancements; and/or pozzolans (Vcas) to neutralize the ASR efflorescence.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: January 10, 2012
    Inventor: Melvin Scott McCombs
  • Publication number: 20100319583
    Abstract: Compositions for fabricating architectural works wherein the compositions utilize one or more cement materials, additives, fibers and recycled glass. Exemplary cement materials include Portland cement, calcium aluminate, fly ash and/or E glass. Exemplary additives include boric acid, citric acid, lithium, plasticizer and/or methylcellulose ethers. Exemplary fibers include polyvinyl alcohol (PVA) and/or micro-fibers. Crushed recycled glass is used as an aggregate or non-reactive material. Other ingredients may be used including: sodium hydroxide, potassium hydroxide and hydrated lime to alter the PH; ferrous sulfate, mono-potassium phosphate, or manganese carbonate and magnesium sulfate as color enhancements; and/or pozzolans (Vcas) to neutralize the ASR efflorescence.
    Type: Application
    Filed: June 17, 2010
    Publication date: December 23, 2010
    Inventor: Melvin Scott McCombs
  • Patent number: 6357196
    Abstract: A hollow fiberglass utility pole includes a pair of segments that are a fiberglass sheet that has a semicircular cross-section. The segments have first and second longitudinal edges with male and female couplers respective shapes that have a complimentary relationship to each other for mechanical engagement thereof. The fiberglass pole is assembled by engaging the first longitudinal edge of one segment with the second longitudinal edge of the other segment at an installation site. The fiberglass pole may be used as a sheath to encase an existing wooden pole.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: March 19, 2002
    Inventor: M. Scott McCombs